PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.35%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
0.52%
Positive gross profit growth while ADI is negative. John Neff would see a clear operational edge over the competitor.
-16.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-5.08%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.78%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-4.81%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-4.90%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.20%
Share change of 0.20% while ADI is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.10%
Diluted share change of 0.10% while ADI is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-0.00%
Dividend reduction while ADI stands at 0.03%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-42.68%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-47.69%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
54.04%
Similar 10Y revenue/share CAGR to ADI's 56.13%. Walter Schloss might see both firms benefiting from the same long-term demand.
24.84%
5Y revenue/share CAGR at 50-75% of ADI's 46.50%. Martin Whitman would worry about a lagging mid-term growth trajectory.
23.53%
3Y revenue/share CAGR under 50% of ADI's 58.48%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
107.34%
10Y OCF/share CAGR above 1.5x ADI's 65.72%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
102.79%
5Y OCF/share CAGR above 1.5x ADI's 41.18%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
86.39%
3Y OCF/share CAGR at 75-90% of ADI's 101.98%. Bill Ackman would press for improvements in margin or overhead to catch up.
179.18%
Net income/share CAGR above 1.5x ADI's 55.43% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
330.89%
5Y net income/share CAGR above 1.5x ADI's 50.23%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
121.75%
3Y net income/share CAGR above 1.5x ADI's 43.91%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
36.24%
Below 50% of ADI's 78.48%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
10.06%
Below 50% of ADI's 33.18%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
8.51%
3Y equity/share CAGR at 50-75% of ADI's 11.91%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
1145.59%
10Y dividend/share CAGR above 1.5x ADI's 159.87%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
193.66%
5Y dividend/share CAGR above 1.5x ADI's 68.06%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
66.64%
3Y dividend/share CAGR above 1.5x ADI's 23.70%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
5.52%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
2.96%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.76%
Negative asset growth while ADI invests at 28.02%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.38%
50-75% of ADI's 2.73%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-6.95%
We’re deleveraging while ADI stands at 119.69%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.58%
R&D growth drastically higher vs. ADI's 6.38%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
6.81%
SG&A growth well above ADI's 9.91%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.